Mar 18, 2022

Featuring perspectives from Dr Andrew Armstrong, including the following topics:

• Introduction: Genitourinary Cancers Symposium 2022 (0:00)
• Case: A man in his late 50s with metastatic hormone-sensitive prostate cancer, a history of breast cancer and a germline BRCA1 mutation — Julia Saylors, MD (17:02)
• Case: A man in his early 70s with multiple prior therapies for metastatic prostate cancer, including lutetium on the VISION trial — Sulfi Ibrahim, MD (22:18)
• Case: A man in his late 80s with metastatic prostate cancer who received leuprolide/enzalutamide/denosumab and sipuleucel-T — Yanjun Ma, MD (31:49)
• Case: A man in his mid-50s with metastatic adenocarcinoma of the prostate with neuroendocrine differentiation (genomic LOH high, germline PALB2 VUS) — Spencer Henick Bachow, MD (34:18)
• Case: A man in his mid-70s with metastatic castration-resistant prostate cancer and Lynch syndrome (BRCA-VUS, MSH6 and BRAF V601E mutations) — Kapisthalam (KS) Kumar, MD (39:47)
• Case: A man in his late 80s with mCRPC and a CHEK2 mutation — Dr Ibrahim (48:11)
• Journal Club with Andrew J Armstrong, MD, ScM (53:36)

CME information and select publications